Glenmark Pharmaceuticals will be in focus as the company’s collaborative partner, Salix Pharmaceuticals on Wednesday, 5 September 2012, announced that the US Food and Drug Administration has advised the company that the new drug application (NDA) for Crofelemer 125 milligram (mg) tablets, indicated for symptomatic relief of non-infectious diarrhea in patients with HIV/AIDS on anti-retroviral therapy is still under review and that a final action will not be taken by the scheduled Prescription Drug User Fee Act.
About author
Market Bureau comprises of team of highly skilled Professionals who have expertise in Financial & Business Reporting. It also includes freelancers ,consultants and authors from our content partners who brings in valued and critical insights to this section with their rich experience. ...more
Market Bureau comprises of team of highly skilled Professionals who have expertise in Financial & Business Reporting. It also includes freelancers ,consultants and authors from our content partners who brings in valued and critical insights to this section with their rich experience. ...more
